A Phase II Trial to Assess the Efficacy of IRESSA™ (Gefitinib) 500 mg/Day in Patients With Breast Cancer Who Have Failed Tamoxifen or Have an Oestrogen Receptor Negative Tumour and Would be Considered for Systemic Therapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective tumour response (complete + partial response) based on Union International Contre le Cancer (UICC) Criteria
Assessed after 24 weeks
No
R Robertson, MD
Principal Investigator
City Hospital, Nottingham , UK
United Kingdom: Medicines and Healthcare Products Regulatory Agency
1839IL/0057
NCT00632723
April 2001
October 2005
Name | Location |
---|